Treatment of Nonalcoholic Steatohepatitis in Adults: Present and Future

Abstract EN

Nonalcoholic steatohepatitis has become one of the most common liver-related health problems.

This condition has been linked to an unhealthy diet and weight gain, but it can also be observed in nonobese people.

The standard of care is represented by the lifestyle intervention.

However, because this approach has several limitations, such as a lack of compliance, the use of many drugs has been proposed.

The first-line pharmacological choices are vitamin E and pioglitazone, both showing a positive effect on transaminases, fat accumulation, and inflammation.

Nevertheless, vitamin E has no proven effect on fibrosis and on long-term morbidity and mortality and pioglitazone has a negative impact on weight.

Other drugs have been studied such as metformin, ursodeoxycholic acid, statins, pentoxiphylline, and orlistat with only partially positive results.

Among the emerging treatments, telmisartan is particularly interesting as it seems to have an impact on insulin resistance, liver steatosis, inflammation, and fibrosis.

However, the pathogenesis of steatohepatitis is highly complex and is determined by different parallel hits; indeed, the association of different drugs that act on various levels has been suggested.

In conclusion, lifestyle intervention should be optimised and the associations of different drugs should be tested in large studies with long-term outcomes.